[1] RIELY G J, WOOD D E, ETTINGER D S, et al. Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2024, 22(4): 249-274. doi:  10.6004/jnccn.2204.0023
[2] JING M, HE X, CAI C Z, et al. Epidermal growth factor receptor regulates lineage plasticity driving transformation to small cell lung cancer[J]. Biochem Biophys Res Commun, 2023, 681: 218-224. doi:  10.1016/j.bbrc.2023.09.047
[3] 朱洪宇, 史志敏. 微小RNA-338-3p调控信号转导和转录激活因子1对表皮生长因子受体酪氨酸激酶抑制剂耐药肺癌细胞株PC-9/GR中程序性死亡配体1表达和细胞凋亡的影响[J]. 实用临床医药杂志, 2022, 26(4): 100-105. doi:  10.7619/jcmp.20213701
[4]

AGUILAR-SERRA J, GIMENO-BALLESTER V, PASTOR-CLERIGUES A, et al. Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer[J]. Expert Rev Pharmacoecon Outcomes Res, 2022, 22(4): 637-646. doi:  10.1080/14737167.2022.1987220
[5]

ZHANG L F, LI N, LIU M B, et al. Cost-effectiveness analysis of dacomitinib versus gefitinib in the first-line treatment of EGFR-positive advanced or metastatic non-small cell lung cancer[J]. Cancer Manag Res, 2021, 13: 4263-4270. doi:  10.2147/CMAR.S293983
[6]

BANNA G L, ADDEO A. Osimertinib after chemoradiotherapy in stage Ⅲ EGFR-mutated NSCLC[J]. 2024, 391(16): 1555.
[7] 王皓, 曾晨欣, 李俐, 等. 奥希替尼和吉非替尼/厄洛替尼一线治疗EGFR突变阳性非小细胞肺癌的成本-效果分析[J]. 医药导报, 2020, 39(12): 1689-1696. doi:  10.3870/j.issn.1004-0781.2020.12.018
[8] 中国医师协会肿瘤医师分会, 中国医疗保健国际交流促进会肿瘤内科分会. 肺癌脑转移中国治疗指南(2021年版)[J]. 中华肿瘤杂志, 2021, 43(3): 269-281. doi:  10.3760/cma.j.cn112152-20210104-00009
[9]

SEYMOUR L, BOGAERTS J, PERRONE A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics[J]. 2017, 18(3): e143-e152.
[10]

PHD P B, NEAL D FREEDMAN PHD M, et al. Lung cancer statistics, 2023[J]. Cancer, 2024, 130(8): 1330-1348. doi:  10.1002/cncr.35128
[11]

CHO B C, AHN M J, KANG J H, et al. Lazertinib versus gefitinib as first-line treatment in patients with EGFR-mutated advanced non-small-cell lung cancer: results from LASER301[J]. J Clin Oncol, 2023, 41(26): 4208-4217. doi:  10.1200/JCO.23.00515
[12] 李倩, 吕姣, 谢晓东, 等. 吉非替尼靶向治疗对晚期老年非小细胞肺癌患者近远期疗效及凝血功能影响[J]. 临床和实验医学杂志, 2021, 20(23): 2523-2527. doi:  10.3969/j.issn.1671-4695.2021.23.016
[13]

HERBST R S, WU Y L, JOHN T, et al. Adjuvant osimertinib for resected EGFR-mutated stage IB-ⅢA non-small-cell lung cancer: updated results from the phase Ⅲ randomized ADAURA trial[J]. J Clin Oncol, 2023, 41(10): 1830-1840. doi:  10.1200/JCO.22.02186
[14]

TSUBOI M, HERBST R S, JOHN T, et al. Overall survival with osimertinib in resected EGFR-mutated NSCLC[J]. 2023, 389(2): 137-147.
[15]

CHENG Y, HE Y, LI W, et al. Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study[J]. Target Oncol, 2021, 16(2): 165-176. doi:  10.1007/s11523-021-00794-6
[16]

POPAT S, AHN M J, EKMAN S, et al. Osimertinib for EGFR-mutant non-small-cell lung cancer central nervous system metastases: current evidence and future perspectives on therapeutic strategies[J]. Target Oncol, 2023, 18(1): 9-24. doi:  10.1007/s11523-022-00941-7
[17]

SHI P Y, ZHANG S, ZHU L, et al. The third-generation EGFR inhibitor, osimertinib, promotes c-FLIP degradation, enhancing apoptosis including TRAIL-induced apoptosis in NSCLC cells with activating EGFR mutations[J]. Transl Oncol, 2019, 12(5): 705-713. doi:  10.1016/j.tranon.2019.02.006
[18]

NAM Y W, SHIN J H, KIM S, et al. Correction: EGFR inhibits TNF-α-mediated pathway by phosphorylating TNFR1 at tyrosine 360 and 401[J]. Cell Death Differ, 2025, 32(6): 1180. doi:  10.1038/s41418-024-01425-z
[19] 刘心怡, 陈文. 奥希替尼用于EGFR+晚期非小细胞肺癌患者一线治疗的药物经济学评价[J]. 世界临床药物, 2021, 42(2): 135-142.